On 12 Nov 2026 West Pharmaceutical Services closed at $411.30, +49.9% this year; market cap $29.12bn, P/E 45.6.
Health Care · Health Care Supplies · NYSE · United States
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
| Market cap | $29.12bn |
| P/E (trailing) | 45.6 |
| EPS (TTM) | $9.02 |
| Beta | 1.14 |
| Dividend | $1.04 |
| Dividend yield | 0.25% |
| Ex-dividend date | 10 Nov 2026 |
| Latest report | 29 Oct 2026 |
| Next earnings | 28 Jan 2027 |
| YTD | +49.9% |
| 1Y | +50.6% |
| 3Y | +7.1% |
| 5Y | -0.1% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $3.07bn | $493.70m | $468.90m |
| 2024 | $2.89bn | $492.70m | $276.40m |
| 2023 | $2.95bn | $593.40m | $414.50m |
| 2022 | $2.89bn | $585.90m | $439.40m |
| 2021 | $2.83bn | $661.80m | $330.60m |
Base value $324.30 (-21.2% vs price); 0 of 1 methods above the price. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.